核糖体蛋白L23参与肿瘤进程的研究

doi:10.3760/cma.j.issn.1673-422X.2016.11.008

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (11): 835-837.doi: 10.3760/cma.j.issn.1673-422X.2016.11.008

核糖体蛋白L23参与肿瘤进程的研究

彭文苗，秦传蓉，张志敏，胡萌，饶智国

430070 武汉，广州军区武汉总医院肿瘤科

收稿日期:2016-05-13 出版日期:2016-11-08 发布日期:2016-11-02
通讯作者: 饶智国，Email: raozhiguo@hotmail.com E-mail:raozhiguo@hotmail.com
基金资助:
湖北省自然科学基金（2014CFC1049）

Research of ribomomal protein L23 in tumor progression

Peng Wenmiao, Qin Chuanrong, Zhang Zhimin, Hu Meng, Rao Zhiguo

epartment of Oncology, Wuhan General Hospital of Guangzhou Military Command, Wuhan 430070, China

Received:2016-05-13 Online:2016-11-08 Published:2016-11-02
Contact: Rao Zhiguo E-mail:raozhiguo@hotmail.com
Supported by:
Natural Science Foundation of Hubei Province of China (2014CFC1049)

摘要/Abstract

摘要： 核糖体蛋白L23是肿瘤基因治疗的新靶点，其通过调控p53激活、灭活鼠双微体2、间接影响cMyc致癌活性、参与肿瘤多药耐药、影响肿瘤生物学行为等方式参与肿瘤进程，是影响肿瘤患者临床预后的潜在因素。

关键词: 肿瘤, 基因, p53, 基因, myc, 抗药性, 多药, 核糖体蛋白L23

Abstract: Ribosomal protein L23 is a new target for gene therapy of cancer. It participates in tumor progression by activating p53, inactivating murine double minute 2, regulating the carcinogenic activity of cMyc, inducing the multidrug resistance, and affecting the biologic behaviour of tumors. Generally, it′s considered to be a potential prognostic factor in human cancers.

Key words: Neoplasms, Genes, p53, Genes, myc, Drug resistance,multiple, Ribosomal protein L23

彭文苗，秦传蓉，张志敏，胡萌，饶智国. 核糖体蛋白L23参与肿瘤进程的研究[J]. 国际肿瘤学杂志, 2016, 43(11): 835-837.

Peng Wenmiao, Qin Chuanrong, Zhang Zhimin, Hu Meng, Rao Zhiguo. Research of ribomomal protein L23 in tumor progression[J]. Journal of International Oncology, 2016, 43(11): 835-837.

参考文献

［1］ Klinge S, VoigtsHoffmann F, Leibundgut MA. Atomic structures of the eukaryotic ribosome［J］. Trends Biochem Sci, 2012, 37(5): 189-198. DOI: 10.1016/j.tibs.2012.02.007. ［2］ Zhou X, Liao WJ, Liao JM, et al. Ribosomal proteins: functions beyond the ribosome［J］. J Mol Cell Biol, 2015, 7(2): 92-104. DOI: 10.1093/jmcb/mjv014. ［3］ Vijayakumaran R, Tan KH, Miranda PJ, et al. Regulation of mutant p53 protein expression［J］. Front Oncol, 2015, 5: 284. DOI: 10.3389/fonc, 2015, 5(12): 00284. ［4］ KarniSchmidt O, Lokshin M, Prives C. The roles of MDM2 and MDMX in cancer［J］. Annu Rev Pathol, 2016, 11(5): 617-644. DOI: 0.1146/annurevpathol012414040349. ［5］ Yu Q, Li Y, Mu K, et al. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations［J］. Diagn Pathol, 2014, 9(1): 1-8. DOI: 10.1186/17461596971. ［6］ Michalk M, Meinrath J, Künstlinger H, et al. MDM2 gene amplification in esophageal carcinoma［J］. Oncol Rep, 2016, 35(4): 2223-2227. DOI: 10.3892/or.2016.4578. ［7］ Javid J, Mir R, Julka PK, et al. Association of p53 and mdm2 in the development and progression of non-small cell lung cancer[J]. Tumour Biol, 2015, 36(7): 5425-5432. DOI: 10.1007/s13277-015-3208-6. [8] Zhuo X, Ye H, Li Q, et al. Is mdm2 SNP309 variation a risk factor for head and neck carcinoma?: An updated meta-analysis based on 11 552 individuals[J]. Medicine, 2016, 95(9): e2948. DOI: 10.1097/MD.0000000000002948. ［9］ Burgess A, Chia K M, Haupt S, et al. Clinical overview of MDM2/Xtargeted therapies［J］. Front Oncol, 2016, 6: 7. DOI: 10.3389/fonc.2016.00007. ［10］ Liu Y, Deisenroth C, Zhang Y. RPMDM2p53 pathway: linking ribosomal biogenesis and tumor surveillance［J］. Trends in Cancer, 2016, 2(4): 191204. DOI: 10.1016/j.trecan.2016.03.002. ［11］ Zhang YF, Zhang BC, Zhang AR, et al. Cotransduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviralmediated p53 gene transfer in human gastric cancer［J］. Oncol Rep, 2013, 30(4): 1989-1995. DOI: 10.3892/or.2013.2663. ［12］ Fang HH, Kang JB, Du R, et al. Growth inhibitory effect of adenovirusmediated tissuetargeted expression of ribosomal protein L23 on human colorectal carcinoma cells［J］. Oncol Rep, 2015, 34(2): 763770. DOI: 10.3892/or.2015.4026. ［13］ Burgess A, Chia KM, Haupt S, et al. Clinical overview of MDM2/Xtargeted therapies［J］. Front Oncol, 2015, 6: 7. DOI: 10.3389/fonc.2016.00007. ［14］ Jung JH, Liao JM, Zhang Q, et al. Inauhzin3(c) inactivates cMyc independently of p53［J］. Cancer Biol Ther, 2015, 16(3): 412-419. DOI: 10.1080/15384047.2014.1002698. ［15］ Bretones G, Delgado MD, León J. Myc and cell cycle control［J］. Biochim Biophys Acta, 2015, 1849(5): 506-516. DOI: 10.1016/j.bbagrm.2014.03.013. ［16］ Sodir NM, Lamorna BS, Karnezis AN, et al. Endogenous Myc maintains the tumor microenvironment［J］. Genes Dev, 2011, 25(9): 907-916. DOI: 10.1101/gad.2038411. ［17］ Van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis［J］. Nat Rev Cancer, 2010, 10(4): 301-309. DOI: 10.1038/nrc2819. ［18］ Zhou X, Hao Q, Liao JM, et al. Ribosomal protein S14 negatively regulates cMyc activity［J］. J Biol Chem, 2013, 288(30): 21793-21801. DOI: 10.1074/jbc.M112.445122. ［19］ Liao JM, Zhou X, Gatignol A, et al. Ribosomal proteins L5 and L11 cooperatively inactivate cMyc via RNAinduced silencing complex［J］. Oncogene, 2014, 33(41): 4916-4923. DOI: 10.1038/onc.2013.430. ［20］ Wanzel M, Russ AC, KleineKohlbrecher DA, et al. A ribosomal protein L23nucleophosmin circuit coordinates Miz1 function with cell growth［J］. Nat Cell Biol, 2008, 10(9): 1051-1061. DOI: 10.1038/ncb1764. ［21］ Vo BT, Wolf E, Kawauchi D, et al. The interaction of Myc with Miz1 defines medulloblastoma subgroup identity［J］. Cancer Cell, 2016, 29(1): 5-16. DOI: 10.1016/j.ccell.2015.12.003. ［22］ Shi Y, Zhai H, Wang X, Han Z, et al. Ribosomal proteins S13 and L23 promote multidrug resistance in gastric cancer cells by suppressing druginduced apoptosis［J］. Exp Cell Res, 2004, 296(2): 337-346. DOI: 10.1016/j.yexcr.2004.02.009. ［23］于海燕, 张志勇, 王凯, 等. 下调RPL23对胃癌耐药细胞SGC7901/ADR药物敏感性的影响［J］. 现代肿瘤医学, 2015, 23(10): 1340-1343. ［24］吴静, 杨睿, 刘树业. 肿瘤多药耐药的产生机制及逆转策略［J］. 国际肿瘤学杂志, 2013, 40(12): 889-892. DOI: 10.3760/cma.j.issn.1673-422X.2013.12.003. ［25］ Salehan MR, Morse HR. DNA damage repair and tolerance: a role in chemotherapeutic drug resistance［J］. Br J Biomed Sci, 2013, 70(1): 31-40. ［26］ Wu L, Li X, Xu F, et al. Overexpression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine［J］. Ann Hematol, 2012, 91(10): 1547-1554. DOI: 10.1007/s00277-012-1486-2. ［27］ de Las HerasRubio A, Perucho L, Paciucci R, et al. Ribosomal proteins as novel players in tumorigenesis［J］. Cancer Metastasis Rev, 2014, 33(1): 115-141. DOI: 10.1007/s10555-013-9460-6.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

核糖体蛋白L23参与肿瘤进程的研究

Research of ribomomal protein L23 in tumor progression

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价